Hudson Acquisition I announced that it has entered into a non-binding letter of intent with a target company for a potential business combination. The target is a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses, according to a press release.
The SPAC raised $60 million in October with plans to target US technology companies, while specifically avoiding any companies in China, Hong Kong or Macau. Read more.
